The study will include hospitalized, moderate COVID-19 cases that have a risk of respiratory failure.~The study will generally consist of:~A short screening phase (1 day) before enrollment and thus treatment decision.~A 21 day treatment phase with one cycle of palbociclib~An up to day 90 Safety Follow-Up Phase~The first three patients will be enrolled and treated one by one; the independent safety data review committee (ISRC) will review each patient after D21 before enrollment of the subsequent patient is permitted.
This is a one-site, interventional, prospective, single-arm, open-label, controlled phase-IIa trial evaluating the safety and efficacy of palbociclib in hospitalized, moderate COVID- 19 cases.